ArticleCancer immunology, immunotherapy : CII2024

Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study.

Jianyun Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.